NCT07237555 is a clinical trial in Severe-stage Glaucoma (Mean Deviation ≤ -20 dB), sponsored by Gangnam Severance Hospital.

Who is sponsoring NCT07237555?

NCT07237555 is sponsored by Gangnam Severance Hospital.

What condition does NCT07237555 study?

NCT07237555 studies Severe-stage Glaucoma (Mean Deviation ≤ -20 dB).

Is NCT07237555 still recruiting?

NCT07237555 is currently active, enrolled. Last updated 20 November 2025.

Last reviewed 2025-11-20 · How we verify

NCT07237555

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CVL Risk After Severe Glaucoma Surgery

Active, enrolled Last updated 20 November 2025

What this trial tests

trial in Severe-stage Glaucoma (Mean Deviation ≤ -20 dB) in 523 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

27 November 2024

Primary endpoint
26 November 2025

26 November 2026

Quick facts

Lead sponsor	Gangnam Severance Hospital
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	523
Start date	27 November 2024
Primary completion	26 November 2025
Estimated completion	26 November 2026
Sites	1 location across South Korea

Conditions studied

Severe-stage Glaucoma (Mean Deviation ≤ -20 dB) — all drugs for Severe-stage Glaucoma (Mean Deviation ≤ -20 dB) →

Sponsor

Gangnam Severance Hospital

Who can join

Eligibility, any sex, with Severe-stage Glaucoma (Mean Deviation ≤ -20 dB). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This retrospective cohort study analyzes risk factors for central visual loss (CVL) after severe-stage glaucoma surgery. The primary hypothesis is that 1) visual prognosis is determined primarily by early postoperative intraocular pressure (IOP) stability rather than surgical choice, and 2) the nature of risk (hypotony vs hypertension) is modified by baseline visual reserve. We analyzed outcomes in 523 patients with severe-stage glaucoma who underwent trabeculectomy or Ahmed glaucoma valve (AGV) implantation, focusing on the dichotomous risk profile stratified by baseline visual acuity.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Gangnam Severance Hospital trials

Trials by the same sponsor.

NCT07505628 — AI-based Rehabilitation for Hip and Knee Surgery Patients · NA · not yet recruiting
NCT07311122 — Endocrine Therapy Base on 21-gene RS · not yet recruiting
NCT07011823 — Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC · Phase 2 · not yet recruiting
NCT07211451 — Axillary Nodal Burden in HER2+ and TNBC · completed
NCT06839716 — Comparison of Ropivacaine-Poloxamer 407 Hydrogel and TAP Block for Postoperative Pain Management in Laparoscopic/Robotic · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07237555 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gangnam Severance Hospital
Last refreshed: 20 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07237555.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing